GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Maxigen Biotech Inc (TPE:1783) » Definitions » ROC (Joel Greenblatt) %

Maxigen Biotech (TPE:1783) ROC (Joel Greenblatt) % : 22.36% (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Maxigen Biotech ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Maxigen Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 22.36%.

The historical rank and industry rank for Maxigen Biotech's ROC (Joel Greenblatt) % or its related term are showing as below:

TPE:1783' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -12.21   Med: 12.68   Max: 42.87
Current: 37.02

During the past 13 years, Maxigen Biotech's highest ROC (Joel Greenblatt) % was 42.87%. The lowest was -12.21%. And the median was 12.68%.

TPE:1783's ROC (Joel Greenblatt) % is ranked better than
85.46% of 846 companies
in the Medical Devices & Instruments industry
Industry Median: -2.045 vs TPE:1783: 37.02

Maxigen Biotech's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 30.80% per year.


Maxigen Biotech ROC (Joel Greenblatt) % Historical Data

The historical data trend for Maxigen Biotech's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maxigen Biotech ROC (Joel Greenblatt) % Chart

Maxigen Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.30 14.44 17.64 33.57 42.87

Maxigen Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.59 55.65 50.24 21.02 22.36

Competitive Comparison of Maxigen Biotech's ROC (Joel Greenblatt) %

For the Medical Instruments & Supplies subindustry, Maxigen Biotech's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maxigen Biotech's ROC (Joel Greenblatt) % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Maxigen Biotech's ROC (Joel Greenblatt) % falls into.



Maxigen Biotech ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(73.459 + 85.185 + 4.735) - (129.214 + 0 + 2.109)
=32.056

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(68.88 + 78.12 + 8.533) - (116.292 + 0 + 19.649)
=19.592

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Maxigen Biotech for the quarter that ended in Mar. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=101.348/( ( (424.178 + max(32.056, 0)) + (430.556 + max(19.592, 0)) )/ 2 )
=101.348/( ( 456.234 + 450.148 )/ 2 )
=101.348/453.191
=22.36 %

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Maxigen Biotech  (TPE:1783) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Maxigen Biotech ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Maxigen Biotech's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Maxigen Biotech (TPE:1783) Business Description

Traded in Other Exchanges
N/A
Address
No. 88, Keji 1st Rd, Guishan District, Taoyuan City, TWN, 333
Maxigen Biotech Inc specializes in the developing, manufacturing, and marketing of biomedical and cosmeceutical skincare products. It provides medical devices for orthopedic, ophthalmic, dental, and surgical applications. Skincare product categories include mask series, facial cleansing series, and body care series. The biomedical products segment is primarily engaged in the manufacturing and sales of collagen and bone materials, which forms the majority chunk of the revenue of the group. The consumer products segment is engaged in the manufacturing and sales of beauty care products.

Maxigen Biotech (TPE:1783) Headlines

No Headlines